Page 18 - Thomask Equels News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Globe Newswire. The AP news staff was not involved in its creation. AIM ImmunoTech Announces First COVID-19-Induced Chronic Fatigue “Long Hauler” Patient Dosed ... AIM ImmunoTech Inc.January 6, 2021 GMT OCALA, Fla., Jan. 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that the active AMP-511 Expanded Access Program (EAP) has dosed its first COVID-19 “Long Hauler” patient with the drug Ampligen (rintatolimod), marking a significant milestone in AIM’s efforts to develop an effective therapeutic for people suffering from ...

Ocala company reveals new COVID-19 drug for virus ‘long haulers’ Additional patients are in the process of being enrolled Thomas Metevia, Digital Content Producer, Orlando Tags:  OCALA, Fla. – There’s a new COVID-19 drug in town and the company behind it hopes the treatment will help those suffering from post-COVID-19 infection chronic fatigue-like symptoms, who have been dubbed “long haulers.” AIM ImmunoTech Inc. announced Wednesday that they officially provide the first dose to their first patient with the drug called Ampligen. [TRENDING: Ad The company believes this to be th...

DGAP-News: AIM I ... DGAP-News: AIM ImmunoTech Inc: AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 Long Haulers vom 24.12.2020, 14:15 Uhr Bild: pixabay.com DGAP-News: AIM ImmunoTech Inc / Key word(s): Miscellaneous AIM ImmunoTech Inc: AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 Long Haulers 24.12.2020 / 14:15 The issuer is solely responsible for the content of this announcement. AIM ImmunoTech Announces that the ME/CFS Clinical Trial of its Drug...

AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 'Long Haulers' Institutional Review Board Authorizes Public Notification for Potential

OCALA, Fla., Dec. 24, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) announced today that the post-COVID-19 "Long Hauler" portion of the active ...